Giorgio Gandaglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4814595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection. European Urology Focus, 2022, 8, 431-437.	1.6	5
2	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 674-689.	1.6	21
3	Re: Paolo Dell'Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery, Eur Urol Focus 2021:7:352–8. European Urology Focus, 2022, 8, 890.	1.6	Ο
4	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non–Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. European Urology Focus, 2022, 8, 690-700.	1.6	10
5	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4
6	Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. BJU International, 2022, 129, 201-207.	1.3	11
7	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. World Journal of Urology, 2022, 40, 103-110.	1.2	9
8	Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. European Urology, 2022, 81, 193-203.	0.9	30
9	An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. Journal of Urology, 2022, 207, 350-357.	0.2	13
10	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. European Urology Oncology, 2022, 5, 1-17.	2.6	50
11	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter Journal of Urology, 2022, 207, 242.	0.2	Ο
12	Improving Guideline Adherence in Urology. European Urology Focus, 2022, 8, 1545-1552.	1.6	5
13	How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 103.e17-103.e24.	0.8	8
14	Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84.	0.9	6
15	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. European Urology Oncology, 2022, 5, 153-163.	2.6	15
16	Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019. European Urology, 2022, 81, e115-e116.	0.9	0
17	Metastases-directed Therapies in the Prostate-specific Membrane Antigen Era: Not All That Glitters Is Curable. European Urology Oncology, 2022, 5, 52-53.	2.6	0
18	Re: Steven MacLennan, Eilidh Duncan, Ted A. Skolarus, et al. Improving Guideline Adherence in Urology. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.10.007. European Urology Focus, 2022, , .	1.6	0

#	ARTICLE	IF	CITATIONS
19	Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5–33. European Urology, 2022, 81, e122.	0.9	0
20	Re: Dries Develtere, Giuseppe Rosiello, Pietro Piazza, et al. Early Catheter Removal on Postoperative Day 2 After Robot-assisted Radical Prostatectomy: Updated Real-life Experience with the Aalst Technique. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.10.003. European Urology Focus, 2022, , .	1.6	0
21	Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes. European Urology Open Science, 2022, 38, 10-11.	0.2	3
22	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210819.	1.4	12
23	Multicentric comparative analysis of Retzius versus Retzius sparing robotic assisted simple prostatectomy in the management of large prostate glands. Scandinavian Journal of Urology, 2022, 56, 119-125.	0.6	1
24	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. European Urology Oncology, 2022, 5, 30-41.	2.6	11
25	Re: K.R. Seetharam Bhat, Marcio Covas Moschovas, Marco Sandri, et al. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/i.euf.2021.10.005. European Urology Focus. 2022	1.6	1
26	Predictors of Unfavorable Pathology in Patients with Incidental (pT1a–T1b) Prostate Cancer. European Urology Focus, 2022, , .	1.6	3
27	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	0.8	4
28	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. European Urology, 2022, 81, 337-346.	0.9	33
29	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. Cancers, 2022, 14, 147.	1.7	2
30	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter Journal of Urology, 2022, , 101097JU0000000000002680.	0.2	0
31	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	0.9	15
32	Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. Prostate, 2022, 82, 1170-1175.	1.2	5
33	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. Journal of Personalized Medicine, 2022, 12, 751.	1.1	Ο
34	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. Prostate, 2022, 82, 1210-1218.	1.2	2
35	Comment on: "The impact of age on pathological insignificant prostate cancer rates in contemporary robot-assisted prostatectomy patients despite active surveillance eligibility". Minerva Urology and Nephrology, 2022, 74, .	1.3	0
36	Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. Journal of Urology, 2022, 208, 1046-1055.	0.2	1

#	Article	IF	CITATIONS
37	Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. European Urology Oncology, 2021, 4, 594-600.	2.6	12
38	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074.	1.6	7
39	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European Urology Oncology, 2021, 4, 971-979.	2.6	56
40	Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel—A Real-world Data Assessment. European Urology Focus, 2021, 7, 1308-1315.	1.6	3
41	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. European Urology Oncology, 2021, 4, 745-754.	2.6	17
42	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. European Urology Focus, 2021, 7, 1092-1099.	1.6	4
43	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World Journal of Urology, 2021, 39, 1947-1953.	1.2	7
44	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. European Urology Oncology, 2021, 4, 1001-1005.	2.6	23
45	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	2.6	20
46	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. European Urology Focus, 2021, 7, 742-751.	1.6	19
47	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. World Journal of Urology, 2021, 39, 813-822.	1.2	6
48	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 48-53.	3.0	30
49	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545
50	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part Il—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 2021, 79, 263-282.	0.9	633
51	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e1-236.e7.	0.8	10
52	Re: Histological comparison between predictive value of preoperative 3â€T multiparametric MRI and 68 Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 746-746.	1.3	0
53	RE: Validating the Martini Staging System for Rectourethral Fistula: A Meta-analysis of Postoperative Outcomes. Urology, 2021, 147, 323.	0.5	0
54	Re: Paolo Afonso de Carvalho, JoÄo A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. Eur Urol 2020;77:628–35. European Urology, 2021, 79. e44-e46.	0.9	4

#	Article	IF	CITATIONS
55	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	0.8	10
56	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 193-201.	2.0	7
57	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. BJU International, 2021, 127, 318-325.	1.3	28
58	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. European Urology Oncology, 2021, 4, 42-48.	2.6	40
59	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology Oncology, 2021, 4, 301-304.	2.6	2
60	Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2021, 205, 340-341.	0.2	0
61	SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SC), and SC plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy Journal of Clinical Oncology. 2021. 39. TPS506-TPS506.	0.8	8
62	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	0.8	4
63	Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. European Urology Focus, 2021, 7, 245-249.	1.6	7
64	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 784.e1-784.e9.	0.8	7
65	Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. Prostate Cancer and Prostatic Diseases, 2021, 24, 1137-1142.	2.0	3
66	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e11-785.e17.	0.8	6
67	Radical Prostatectomy: Sequelae in the Course of Time. Frontiers in Surgery, 2021, 8, 684088.	0.6	4
68	Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537–44. European Urology, 2021, 79, e132-e133.	0.9	0
69	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e21-296.e29.	0.8	24
70	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2021, 80, 531-545.	0.9	21
71	Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/i.eururo.2020.11.040. European Urology. 2021. 79. e154-e156.	0.9	1
72	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Letter Journal of Urology, 2021, 205, 1839-1839.	0.2	0

#	Article	IF	CITATIONS
73	RE: Retzius Sparing Prostatectomy Effect on Symptomatic Lymphocele Rates. Urology, 2021, 152, 205.	0.5	1
74	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. European Urology Oncology, 2021, 4, 405-423.	2.6	26
75	Focal Therapy for Prostate Cancer: Complications and Their Treatment. Frontiers in Surgery, 2021, 8, 696242.	0.6	13
76	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. Frontiers in Surgery, 2021, 8, 691473.	0.6	5
77	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Letter Journal of Urology, 2021, 206, 173-173.	0.2	Ο
78	Followup of Men with PI-RADSâ,,¢ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter Journal of Urology, 2021, 206, 1335.	0.2	1
79	A realâ€world comparison of docetaxel versus abiraterone acetate for metastatic hormoneâ€sensitive prostate cancer. Cancer Medicine, 2021, 10, 6354-6364.	1.3	7
80	Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated With Bacillus Calmette-GuA©rin: Implications for Clinical Trial Design. Letter Journal of Urology, 2021, 206, 1528.	0.2	0
81	Reply by Authors. Journal of Urology, 2021, 206, 645-645.	0.2	Ο
82	Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy. Journal of Urology, 2021, 206, 638-645.	0.2	8
83	Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567–72. European Urology, 2021, 80, e147-e148.	0.9	0
84	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. Minerva Urology and Nephrology, 2021, 73, 481-488.	1.3	5
85	Re: Marra etÂal . †Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'. BJU International, 2021, 128, 523-523.	1.3	1
86	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study. Central European Journal of Urology, 2021, 74, 362-365.	0.2	3
87	Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 697-713.	2.6	84
88	Epidemiology and Prevention of Prostate Cancer. European Urology Oncology, 2021, 4, 877-892.	2.6	190
89	Reimagining prostate cancer screening: the IMPACT of germline mutations. Lancet Oncology, The, 2021, 22, 1491-1492.	5.1	3
90	Evidence-based Urology: Surrogate Endpoints – Pro. European Urology Focus, 2021, 7, 1217-1218.	1.6	3

#	Article	IF	CITATIONS
91	There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. European Urology Oncology, 2020, 3, 112-118.	2.6	40
92	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. European Urology, 2020, 77, 733-741.	0.9	85
93	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 204-209.	0.8	8
94	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	0.9	228
95	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. Prostate Cancer and Prostatic Diseases, 2020, 23, 260-268.	2.0	5
96	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer, 2020, 18, 35-44.e1.	0.9	2
97	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	0.9	75
98	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. European Urology, 2020, 77, 576-580.	0.9	55
99	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. European Urology Oncology, 2020, 3, 474-480.	2.6	15
100	Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443–51. European Urology, 2020, 78, e165.	0.9	1
101	Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxleya€ Ins Letter to the Editor re: Glorgio Gandagila, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical	0.9	1
102	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	3.4	49
103	Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009. European Urology, 2020, 78, e67-e68.	0.9	0
104	Key Prerequisites for the Correct Management of Intermediate-risk Prostate Cancer. European Urology Oncology, 2020, 3, 281-282.	2.6	0
105	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253.	1.6	7
106	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy. European Urology Oncology, 2020, 3, 739-747.	2.6	31
107	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581.	2.6	46
108	Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer—Not All That Glitters Is Gold. JAMA Oncology, 2020, 6, 1638.	3.4	1

#	Article	IF	CITATIONS
109	Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery. IEEE Transactions on Medical Robotics and Bionics, 2020, 2, 148-156.	2.1	10
110	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	0.9	128
111	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 573-580.	2.0	22
112	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. European Urology, 2020, 77, 614-627.	0.9	101
113	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. European Urology, 2020, 78, 661-669.	0.9	74
114	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. European Urology, 2020, 78, 779-782.	0.9	16
115	ProstaTrend—A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. European Urology, 2020, 78, 452-459.	0.9	15
116	Re: Aurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826–33. European Urology, 2020, 77, e137.	0.9	0
117	Re: Ola Bratt, Erik Holmberg, Ove Andrén, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol 2019;76:461–6. European Urology, 2020, 77, e136	0.9	0
118	Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106–14. European Urology, 2020, 77, e107.	0.9	0
119	Rates of otherâ€cause mortality after radical cystectomy are decreasing over time—A populationâ€based analysis over two decades. Journal of Surgical Oncology, 2020, 121, 1329-1336.	0.8	5
120	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. European Urology, 2020, 78, 138-142.	0.9	55
121	Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. Frontiers in Oncology, 2020, 10, 607923.	1.3	7
122	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. Journal of Urology, 2020, 203, 338-343.	0.2	53
123	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections Journal of Urology 2020 204 296-302	0.2	32
124	Reply by Authors. Journal of Urology, 2020, 204, 302-302.	0.2	0
125	Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer. Journal of Urology, 2020, 204, 587-587.	0.2	0
126	Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. Journal of Urology, 2020, 204, 843-843.	0.2	1

#	Article	IF	CITATIONS
127	Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. World Journal of Urology, 2019, 37, 221-234.	1.2	25
128	Imaging modalities in synchronous oligometastatic prostate cancer. World Journal of Urology, 2019, 37, 2573-2583.	1.2	16
129	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. World Journal of Urology, 2019, 37, 243-251.	1.2	37
130	Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol 2019;76:284–303. European Urology, 2019, 76, e132.	0.9	0
131	The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. Lancet Oncology, The, 2019, 20, 1193-1195.	5.1	4
132	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	0.9	151
133	Hereditary prostate cancer – Primetime for genetic testing?. Cancer Treatment Reviews, 2019, 81, 101927.	3.4	20
134	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e1153-e1162.	0.9	8
135	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	1.1	8
136	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. European Urology Oncology, 2019, 2, 541-548.	2.6	31
137	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 142-150.	0.9	80
138	Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?. Cancer Treatment Reviews, 2019, 75, 20-26.	3.4	23
139	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	0.9	14
140	Robot-assisted versus open cystectomy in the RAZOR trial. Lancet, The, 2019, 393, 645.	6.3	2
141	Requiem for Open Radical Cystectomy in Bladder Cancer Patients. European Urology Oncology, 2019, 2, 196-197.	2.6	2
142	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2019, 2, 456-463.	2.6	13
143	Re: Tom A. Hueting, Erik B. Cornel, Diederik M. Somford, et al. External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. Eur Urol Oncol 2018;1:411–7. European Urology Oncology, 2019, 2, 337.	2.6	0
144	What is new in robot-assisted radical prostatectomy. Current Opinion in Urology, 2019, 29, 14-18.	0.9	4

#	Article	IF	CITATIONS
145	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. European Urology, 2019, 75, 817-825.	0.9	17
146	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2019, 17, 105-113.e2.	0.9	15
147	Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience. European Urology, 2019, 75, 871-874.	0.9	8
148	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. European Urology, 2019, 75, 506-514.	0.9	188
149	Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641–2. European Urology, 2019, 75, e31.	0.9	Ο
150	Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. European Urology, 2019, 76, 493-504.	0.9	111
151	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. European Urology, 2019, 75, 176-183.	0.9	101
152	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. World Journal of Urology, 2019, 37, 1127-1135.	1.2	9
153	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. European Urology Focus, 2019, 5, 171-178.	1.6	50
154	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	1.6	12
155	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus, 2019, 5, 545-549.	1.6	5
156	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. European Urology Focus, 2019, 5, 449-456.	1.6	11
157	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. Journal of Urology, 2019, 202, 108-113.	0.2	67
158	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. Journal of Urology, 2019, 202, 725-731.	0.2	62
159	Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 38-46.	3.9	13
160	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC) Journal of Clinical Oncology, 2019, 37, 391-391.	0.8	1
161	Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017:72:910–7. European Urology. 2018. 73. e131-e132.	0.9	0
162	Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology. World Journal of Urology, 2018, 36, 1489-1494.	1.2	1

#	Article	IF	CITATIONS
163	Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?. European Urology, 2018, 74, 131-133.	0.9	14
164	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	0.8	6
165	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 425-438.	1.3	17
166	Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study. Urology, 2018, 113, 85-90.	0.5	17
167	The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. European Urology, 2018, 74, 4-7.	0.9	50
168	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	0.9	13
169	Urology Residency Training in Italy: Results of the First National Survey. European Urology Focus, 2018, 4, 280-287.	1.6	43
170	â€~Trifecta' outcomes of robotâ€assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis. BJU International, 2018, 121, 119-123.	1.3	27
171	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology, 2018, 73, 890-896.	0.9	87
172	Identifying candidates for superâ€extended staging pelvic lymph node dissection among patients with highâ€risk prostate cancer. BJU International, 2018, 121, 421-427.	1.3	24
173	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology, 2018, 36, 7-13.	1.2	23
174	Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910–7. European Urology, 2018, 73, e36-e37.	0.9	0
175	Depressive Symptoms and Low Sexual Desire after Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting. Journal of Urology, 2018, 199, 474-480.	0.2	23
176	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	0.9	36
177	Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World Journal of Urology, 2018, 36, 157-170.	1.2	91
178	First North American validation and headâ€ŧoâ€head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	1.3	32
179	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	0.6	37
180	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	0.9	60

#	Article	IF	CITATIONS
181	Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy. Translational Andrology and Urology, 2018, 7, S141-S143.	0.6	4
182	Knowledge Transfer and Guidelines Implementation in Genitourinary Cancers. European Urology Oncology, 2018, 1, 426-427.	2.6	1
183	A Novel Classification Proposal for Rectourethral Fistulas After Primary Treatment of Prostate Cancer. European Urology Oncology, 2018, 1, 510-511.	2.6	11
184	Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. Eur Urol 2018;74:4–7. European Urology, 2018, 74, e116-e117.	0.9	0
185	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 488-497.	0.8	Ο
186	Techniques to Improve Sexual Function Following Robot-Assisted Radical Prostatectomy. , 2018, , 401-407.		0
187	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms. , 2018, , 317-330.		о
188	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 529.e11-529.e22.	0.8	31
189	Robotic Urologic Surgery: How to Make an Effective Robotic Program—A European Perspective. , 2018, , 129-140.		ο
190	How can we expand active surveillance criteria in patients with low―and intermediate―isk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. BJU International, 2018, 122, 823-830.	1.3	27
191	Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 120-128.	2.6	55
192	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. Clinical Genitourinary Cancer, 2018, 16, 376-384.e1.	0.9	27
193	External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 364.e1-364.e7.	0.8	13
194	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. European Urology Oncology, 2018, 1, 46-53.	2.6	53
195	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 29-36.	2.6	43
196	Interim results from PURE-01: A phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC) Journal of Clinical Oncology, 2018, 36, TPS533-TPS533.	0.8	4
197	Erectile Dysfunction and Penile Rehabilitation After Robot-Assisted Radical Prostatectomy. , 2018, , 455-462.		1
198	Abstract CT003: Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase II PURE-01 study. , 2018, , .		1

#	Article	IF	CITATIONS
199	Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. European Urology, 2017, 71, 249-256.	0.9	73
200	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 335-341.	0.8	66
201	Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?. Journal of Clinical Oncology, 2017, 35, 469-470.	0.8	4
202	Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol 2017;72:289–92. Do the Data Violate Kaplan-Meier Assumptions?. European Urology, 2017, 72, e31.	0.9	2
203	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. European Urology, 2017, 72, 689-709.	0.9	73
204	Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?. BJU International, 2017, 119, 652-653.	1.3	0
205	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. European Urology, 2017, 72, 632-640.	0.9	165
206	MP64-02 ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY: A MULTICENTRE SERIES OF 243 PATIENTS. Journal of Urology, 2017, 197, .	0.2	0
207	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. Clinical Genitourinary Cancer, 2017, 15, e793-e800.	0.9	51
208	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2017, 72, 910-917.	0.9	21
209	Obesity and prostate cancer. Current Opinion in Urology, 2017, 27, 415-421.	0.9	40
210	The role of prostatic inflammation in the development and progression of benign and malignant diseases. Current Opinion in Urology, 2017, 27, 99-106.	0.9	54
211	PD51-10 SURVIVAL AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PSA PERSISTENCE: THE IMPACT OFÂCOMPETING CAUSES OF MORTALITY. Journal of Urology, 2017, 197, .	0.2	0
212	MP77-20 MULTIPARAMETRIC MRI REPRESENTS AN ADDED VALUE BUT NOT A SUBSTITUTE OF FOLLOW-UP BIOPSIES IN PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	0
213	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e7-461.e14.	0.8	19
214	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. Prostate, 2017, 77, 928-933.	1.2	8
215	An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. Urology Case Reports, 2017, 12, 34-36.	0.1	5
216	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. Urologia Internationalis, 2017, 98, 290-297.	0.6	8

#	Article	IF	CITATIONS
217	Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?. European Urology, 2017, 71, 693-694.	0.9	9
218	Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 150.e9-150.e15.	0.8	40
219	New surgical approaches for clinically high-risk or metastatic prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 1013-1031.	1.1	9
220	MP77-01 11C-CHOLINE VERSUS 68GA-PSMA PET/CT SCAN FOR THE DETECTION OF NODAL RECURRENCE FROM PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SALVAGE LYMPH NODE DISSECTION SERIES. Journal of Urology, 2017, 197, .	0.2	0
221	MP93-02 COMPARISON OF ONCOLOGICAL OUTCOMES BETWEEN OPEN VERSUS ROBOT-ASSISTED SALVAGE RADICAL PROSTATECTOMY: A RETROSPECTIVE MULTICENTRE SERIES. Journal of Urology, 2017, 197, .	0.2	0
222	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. Journal of Endourology, 2017, 31, 872-877.	1.1	43
223	PD03-03 DOES PROSTATE CANCER REPRESENT THE MAIN CAUSE OF DEATH IN ALL NODE POSITIVE PROSTATE CANCER PATIENTS? THE IMPACT OF COMPETING CAUSES OF MORTALITY ACCORDING TO TUMOR CHARACTERISTICS AND RECURRENCE STATUS. Journal of Urology, 2017, 197, .	0.2	0
224	MP77-16 FIRST REPEATED BIOPSY REPRESENTS THE MOST INFORMATIVE PREDICTOR OF PROGRESSION-FREE SURVIVAL AT 3 YEARS FOLLOW-UP IN PATIENTS INCLUDED IN AN ACTIVE SURVEILLANCE PROTOCOL FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	1
225	PD51-08 ASSESSING THE 20-YEAR OUTCOMES OF RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2017, 197, .	0.2	0
226	PD47-12 INCIDENCE RATES AND CANCER CONTROL OUTCOMES OF CONTEMPORARY PRIMARY NEUROENDOCRINE PROSTATE CANCER: ANALYSIS OF SEER DATABASE. Journal of Urology, 2017, 197, .	0.2	0
227	MP97-08 PREDICTION OF EXTREME UPGRADE FROM BIOPSY GRADE 1 TO GRADE 4 OR 5 AT RADICAL PROSTATECTOMY: THE IMPORTANCE OF THE EXTENT OF BIOPSY SAMPLING. Journal of Urology, 2017, 197, .	0.2	0
228	PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OFÂPOST-PROSTATECTOMY RADIATION THERAPY: AÂLONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	0
229	PD15-08 ASSOCIATION BETWEEN EARLY URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: DEVELOPMENT OF A NOVEL POSTOPERATIVE RISK SCORE TO OPTIMIZE PATIENT COUNSELING AND FOLLOW-UP. Journal of Urology, 2017, 197, .	0.2	Ο
230	MP03-05 NOT ALL MPMRI TARGETED BIOPSIES ARE EQUAL: THE IMPACT OF THE TYPE OF APPROACH AND OPERATOR EXPERTISE ON THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.2	0
231	MP64-10 IS THERE AN AGE LIMIT FOR THE INDICATION OF EXTENDED PELVIC LYMPH NODE DISSECTION DURING RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER?. Journal of Urology, 2017, 197, .	0.2	Ο
232	MP97-12 CHANGES OVER TIME IN NODE POSITIVE PROSTATE CANCER RATES AND FEATURES AMONG MEN TREATED WITH RADICAL PROSTATECTOMY AND EXTENTED PELVIC LYMPH NODE DISSECTION AT A SINGLE REFERRAL CENTER. Journal of Urology, 2017, 197, .	0.2	0
233	MP03-04 DOES THE INCLUSION OF NON-INDEX LESIONS AT BIOPSY IMPROVE OUR ABILITY TO PREDICT ADVERSE PATHOLOGIC OUTCOMES AT RADICAL PROSTATECTOMY? IMPLICATIONS FOR TARGETED PLUS SYSTEMATIC BIOPSY SCHEMES. Journal of Urology, 2017, 197, .	0.2	0
234	PD37-05 IMPACT OF STAGE MIGRATION ON METASTATIC PROSTATE CANCER: EVIDENCE OF MORE FAVOURABLE DISEASE CHARACTERISTICS OVER TIME. Journal of Urology, 2017, 197, .	0.2	0

#	Article	IF	CITATIONS
235	MP54-15 PURE BUT NOT MIXED HISTOLOGICAL VARIANTS ARE ASSOCIATED WITH POOR SURVIVAL AT RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS. Journal of Urology, 2017, 197, .	0.2	0
236	MP77-15 INCLUSION OF MPMRI INTO THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) RISK CALCULATOR: A NEW PROPOSAL TO IMPROVE THE ACCURACY OF PROSTATE CANCER DETECTION. Journal of Urology, 2017, 197, .	0.2	1
237	PD51-01 ARE THE RESULTS OF THE PROTECT TRIAL APPLICABLE TO CONTEMPORARY PROSTATE CANCER PATIENTS TREATED AT TWO HIGH-VOLUME EUROPEAN INSTITUTIONS?. Journal of Urology, 2017, 197, .	0.2	0
238	PD51-11 PATHOLOGICAL FINDINGS AT RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE IN LOW-RISK PROSTATE CANCER PATIENTS. DID WE MISS THE CHANCE TO CURE?. Journal of Urology, 2017, 197, .	0.2	0
239	MP97-07 IMPACT OF REVERSE STAGE MIGRATION ON THE OUTCOME OF NODE POSITIVE PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A LARGE, TWO-CENTER EXPERIENCE. Journal of Urology, 2017, 197, .	0.2	0
240	PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: AÂLONG-TERM SURVIVAL ANALYSIS. Journal of Urology, 2017, 197, .	0.2	1
241	PD15-10 SURGICAL EXPERTISE IS THE MAJOR DETERMINANT OF DECREASED COMPLICATION RATES IN CONTEMPORARY PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.2	0
242	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 659.e7-659.e12.	0.8	0
243	Lymph node dissection in urological cancers: one topic, many controversies. World Journal of Urology, 2017, 35, 493-495.	1.2	0
244	Low Pressure Robot-assisted Radical Prostatectomy With the AirSeal System at OLV Hospital: Results From a Prospective Study. Clinical Genitourinary Cancer, 2017, 15, e1029-e1037.	0.9	22
245	Longâ€ŧerm utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU International, 2017, 120, 69-75.	1.3	10
246	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two enter Validation Study. Prostate, 2017, 77, 263-273.	1.2	22
247	Comment on †Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'. British Journal of Cancer, 2017, 116, e3-e3.	2.9	1
248	Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. Prostate, 2017, 77, 234-241.	1.2	4
249	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3NO Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-Institutional Series. European Urology, 2017, 71, 886-893.	0.9	77
250	Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. European Urology, 2017, 72, 289-292.	0.9	81
251	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. European Urology, 2017, 72, 432-438.	0.9	49
252	Robotic Assisted Simple Prostatectomy versus Holmium Laser Enucleation of the Prostate for Lower Urinary Tract Symptoms in Patients with Large Volume Prostate: A Comparative Analysis from a High Volume Center. Journal of Urology, 2017, 197, 1108-1114.	0.2	77

#	Article	IF	CITATIONS
253	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. Journal of Urology, 2017, 197, 669-675.	0.2	55
254	Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: NicolÃ ² Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022. European Urology, 2017, 71, e92-e93.	0.9	1
255	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 67-71.	0.9	14
256	Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?. European Urology, 2017, 71, 379-380.	0.9	6
257	Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. European Urology, 2017, 71, 945-951.	0.9	63
258	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. Urologia, 2017, 84, 9-19.	0.3	25
259	Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. Minerva Urology and Nephrology, 2017, 69, 173-180.	1.3	4
260	Short- and long-term outcomes of salvage lymph node dissection in patients with clinically recurrent prostate cancer Journal of Clinical Oncology, 2017, 35, 255-255.	0.8	0
261	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Canadian Urological Association Journal, 2016, 10, 82.	0.3	21
262	Impact of stage migration and practice changes on highâ€risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU International, 2016, 117, 740-747.	1.3	28
263	<scp>URB</scp> 937, a peripherally restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E ₂ â€induced bladder overactivity and hyperactivity of bladder mechanoâ€afferent nerve fibres in rats. BJU International, 2016, 117, 821-828.	1.3	25
264	When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database. Journal of Endourology, 2016, 30, 201-207.	1.1	12
265	Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians. Journal of Endourology, 2016, 30, 792-798.	1.1	29
266	Re: Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 398.	0.9	1
267	MP14-10 DETRIMENTAL ROLE OF PRE-PROSTATECTOMY NEOADJUVANT ANDROGEN DEPRIVATION IN NODE-NEGATIVE PATIENTS TREATED WITH ADJUVANT RT. Journal of Urology, 2016, 195, .	0.2	Ο
268	PD37-06 CAN WE PREDICT LATE RECURRENCES AFTER RADICAL PROSTATECTOMY IN MEN WITH HIGH RISK PROSTATE CANCER? A VERY LONG TERM ANALYSIS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
269	MP40-11 THE ROLE OF ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM A MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2016, 195, .	0.2	0
270	MP18-09 WHEN IS TUMOUR VOLUME AN EXCLUSION CRITERIA FOR FOCAL THERAPY? RESULTS FROM A RADICAL PROSTATECTOMY SERIES. Journal of Urology, 2016, 195, .	0.2	0

#	Article	IF	CITATIONS
271	PD30-06 ASSESSING THE ROLE OF TIME FROM PROSTATE CANCER DIAGNOSIS TO RADICAL PROSTATECTOMY: CAN SURGERY BE POSTPONED SAFELY?. Journal of Urology, 2016, 195, .	0.2	0
272	Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?. European Urology, 2016, 69, 852-853.	0.9	3
273	MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
274	PD39-04 TIMING OF BLOOD TRANSFUSION AND NOT ABO BLOOD TYPE IS ASSOCIATED WITH SURVIVAL IN PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR NON-METASTATIC BLADDER CANCER: RESULTS FROM A SINGLE HIGH-VOLUME INSTITUTION. Journal of Urology, 2016, 195, .	0.2	0
275	MP80-20 LONG-TERM FUNCTIONAL OUTCOMES OF PROSTATE CANCER PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	0
276	MP11-12 LIVE STREAMING OF ROBOTIC SURGERY FROM LEADING EDUCATIONAL CENTRES ENABLES A GLOBAL APPROACH TO SURGICAL TEACHING Journal of Urology, 2016, 195, .	0.2	1
277	MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3NO PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
278	MP49-03 COMPARATIVE EFFECTIVENESS OF ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY: CANCER CONTROL. Journal of Urology, 2016, 195, .	0.2	0
279	PD43-10 HYPOGONADISM INDEPENDENTLY PREDICTS PATHOLOGICAL GLEASON PATTERN 5 AT THE TIME OF RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	0
280	MP09-05 DOES THE NEW PROSTATE CANCER GRADING SYSTEM IMPROVE PREDICTION OF CLINICAL RECURRENCE?. Journal of Urology, 2016, 195, .	0.2	0
281	MP14-06 THE IMPACT OF ADJUVANT RADIOTHERAPY ON CANCER-SPECIFIC MORTALITY IN PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVOLVEMENT: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
282	MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS. Journal of Urology, 2016, 195, .	0.2	0
283	MP14-19 THE TIME ELAPSED BETWEEN RADICAL PROSTATECTOMY AND POST-OPERATIVE RADIOTHERAPY HAS A SIGNIFICANT IMPACT ON THE SUBSEQUENT ERECTILE FUNCTION RECOVERY RATES. Journal of Urology, 2016, 195, .	0.2	0
284	Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?. European Urology, 2016, 70, 899-900.	0.9	0
285	Perioperative and oncologic outcomes of robot-assisted vs. open radical cystectomy in bladder cancer patients: A comparison of two high-volume referral centers. European Journal of Surgical Oncology, 2016, 42, 1736-1743.	0.5	49
286	Validation of the American Society for Reproductive Medicine guidelines/recommendations in white European men presenting for couple's infertility. Fertility and Sterility, 2016, 106, 1076-1082.e1.	0.5	17
287	STAMPEDE trial and patients with non-metastatic prostate cancer. Lancet, The, 2016, 388, 234-235.	6.3	3
288	Robot-assisted partial nephrectomy. International Journal of Surgery, 2016, 36, 554-559.	1.1	41

#	Article	IF	CITATIONS
289	Timing of androgen-deprivation therapy for prostate cancer: still a long way to go. Lancet Oncology, The, 2016, 17, e313.	5.1	2
290	Editorial Comment to Relationship between androgen deprivation therapy and communityâ€acquired respiratory infections in patients with prostate cancer. International Journal of Urology, 2016, 23, 312-312.	0.5	0
291	Salvage radiotherapy for patients with rising PSA. Lancet Oncology, The, 2016, 17, e314-e315.	5.1	0
292	Rationale for local treatment in the management of metastatic prostate cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 266-272.	0.5	6
293	Editorial Comment to Perioperative blood transfusion in radical cystectomy: Analysis of the National Surgical Quality Improvement Program database. International Journal of Urology, 2016, 23, 750-751.	0.5	0
294	Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 2016, 23, 572-579.	0.5	16
295	Effectiveness of a Combination of Cranberries, Lactobacillus rhamnosus , and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study. European Urology, 2016, 70, 912-915.	0.9	22
296	MP09-14 EXTERNAL VALIDATION OF A MODEL PREDICTING SURVIVALÂOF MEN WITH RECURRENT PROSTATE CANCERÂAFTER RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	0
297	MP75-16 OUTCOMES OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY IN PATIENTS WITH COMPLEX RENAL TUMORS AND PRE-EXISTING CHRONIC KIDNEY DISEASE: A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.2	0
298	MP57-20 PATTERNS OF CLINICAL RECURRENCE AND PREDICTORS OF SYSTEMIC PROGRESSION OF PROSTATE CANCER PATIENTS WITH PSA PERSISTENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.2	0
299	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. Journal of Sexual Medicine, 2016, 13, 669-678.	0.3	15
300	MP09-09 HISTORICAL TRENDS IN HIGH-RISK PROSTATE CANCER PATIENTS CHARACTERISTICS: A 27 YEARS OLD OBSERVATIONAL STUDY FROM A MULTICENTER PROSTATE CANCER CLINICAL AND TRANSLATIONAL RESEARCH GROUP. Journal of Urology, 2016, 195, .	0.2	0
301	The European Association of Urology Robotic Training Curriculum: An Update. European Urology Focus, 2016, 2, 105-108.	1.6	21
302	MP80-02 LATE RECOVERY OF ERECTILE FUNCTION IN MEN TREATED WITH ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: A NOVEL NOMOGRAM DEVELOPMENT AND VALIDATION. Journal of Urology, 2016, 195, .	0.2	0
303	Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol 2016;70:588–96. European Urology, 2016, 70, e108-e109.	0.9	1
304	How can we optimize the use of prostate cancer registries?. Future Oncology, 2016, 12, 1093-1095.	1.1	0
305	Prostate Cancer Registries: Current Status and Future Directions. European Urology, 2016, 69, 998-1012.	0.9	56
306	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology, 2016, 88, 97-103.	0.5	11

#	Article	IF	CITATIONS
307	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. Clinical Genitourinary Cancer, 2016, 14, e341-e346.	0.9	10
308	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. European Urology Focus, 2016, 2, 86-91.	1.6	20
309	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e7-256.e13.	0.8	20
310	Oncologic Outcomes of Robot-Assisted Radical Cystectomy: Results of a High-Volume Robotic Center. Journal of Endourology, 2016, 30, 75-82.	1.1	20
311	Novel Technologies in Urologic Surgery: a Rapidly Changing Scenario. Current Urology Reports, 2016, 17, 19.	1.0	13
312	Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease. European Urology, 2016, 70, 219-222.	0.9	26
313	The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer—The Problem Is How to Avoid Finding These Cancers. European Urology, 2016, 70, 547-548.	0.9	18
314	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. European Urology, 2016, 70, 429-435.	0.9	16
315	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. European Urology, 2016, 69, 1142-1148.	0.9	60
316	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. European Journal of Cancer, 2016, 54, 27-34.	1.3	26
317	Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer. European Urology, 2016, 69, 370.	0.9	0
318	Early Catheter Removal after Robot-assisted Radical Prostatectomy: Surgical Technique and Outcomes for the Aalst Technique (ECaRemA Study). European Urology, 2016, 69, 917-923.	0.9	47
319	Orgasmic Dysfunction After Robot-assisted Versus Open Radical Prostatectomy. European Urology, 2016, 70, 223-226.	0.9	36
320	A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. World Journal of Urology, 2016, 34, 207-213.	1.2	14
321	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e15-59.e22.	0.8	16
322	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	0.9	102
323	Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. European Urology, 2016, 69, 193-196.	0.9	27
324	Do We Need a Novel Nephrometry Scoring System in Partial Nephrectomy?. European Urology, 2016, 69, 80-81.	0.9	3

#	Article	IF	CITATIONS
325	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e1-57.e7.	0.8	21
326	Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013–4. European Urology, 2016, 69, 1015.	0.9	1
327	Comparing longâ€term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU International, 2016, 117, 604-610.	1.3	68
328	MP32-08 READMISSIONS AFTER MAJOR UROLOGIC CANCER SURGERY. Journal of Urology, 2015, 193, .	0.2	1
329	MP4-16 PATTERNS OF CLINICAL RECURRENCE AND IMPACT OF SITEÂOFÂMETASTASIS ON MORTALITY OF PATIENTS WITH NODEÂPOSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2015, 193, .	0.2	0
330	MP83-08 THIRTY YEARS OF RADICAL PROSTATECTOMIES AT A SINGLE TERTIARY CARE REFERRAL CENTER. Journal of Urology, 2015, 193, .	0.2	0
331	MP78-13 PROGNOSTIC VALUE OF TUMOR VOLUME ON DISEASE PROGRESSION OF PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR NODE POSITIVE PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
332	MP56-10 LONG-TERM SURVIVAL PATTERNS OF YOUNG PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY. RESULTS OF A MULTI INSTITUTIONAL, CONDITIONAL SURVIVAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
333	MP56-16 VERY LONG TERM OUTCOMES OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS FROM A SINGLE INSTITUTION SERIES. Journal of Urology, 2015, 193, .	0.2	0
334	MP48-13 IDENTIFICATION OF PATHOLOGICALLY FAVORABLE DISEASE IN INTERMEDIATE RISK PROSTATE CANCER PATIENTS: IMPLICATIONS FOR SELECTION OF ACTIVE SURVEILLANCE CANDIDATES. Journal of Urology, 2015, 193, .	0.2	0
335	MP56-05 EARLY POST-OPERATIVE PSA AFTER RADICAL PROSTATECTOMY IS A MAJOR PREDICTOR OF PROGRESSION AND DEATH IN PATIENTS WITH LYMPH NODE METASTASES. RESULTS FROM A TERTIARY CARE CENTER. Journal of Urology, 2015, 193, .	0.2	0
336	MP82-02 LONG-TERM OUTCOMES OF PATIENTS WITH SEMINAL VESICLE INVASION AT RADICAL PROSTATECTOMY: THE IMPORTANCE OF A MULTIMODAL APPROACH TO INCREASE PATIENT SURVIVAL. Journal of Urology, 2015, 193, .	0.2	0
337	MP44-04 NEPHRON-SPARING SURGERY PROTECTS FROM CHRONIC KIDNEY DISEASE RELATIVE TO RADICAL NEPHRECTOMY BUT DOES NOT IMPACT ON OTHER-CAUSES MORTALITY: LONG-TERM (MORE THAN 10 YEARS) SURVIVAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH A T1A-T1B RENAL MASS. Journal of Urology, 2015, 193.	0.2	5
338	MP4-14 LONG-TERM CANCER CONTROL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS Journal of Urology, 2015, 193, .	0.2	0
339	PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÃVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	2
340	MP82-03 SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: WHICH PATIENTS DO BENEFIT FROM THIS APPROACH?. Journal of Urology, 2015, 193, .	0.2	0
341	MP83-17 IMPACT OF INTRA-OPERATIVE TRANSFUSION ON SURVIVAL OF PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	0
342	MP59-18 COMPREHENSIVE ASSESSMENT OF CONTEMPORARY SHORT-, INTERMEDIATE-, AND LONG-TERM ENDPOINTS AFTER EITHER PARTIAL NEPHRECTOMY OR MINIMALLY-INVASIVE RADICAL NEPHRECTOMY. Journal of Urology, 2015, 193, .	0.2	0

#	Article	IF	CITATIONS
343	MP78-15 BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: WHO IS AT RISK OF DYING FROM PROSTATE CANCER?. Journal of Urology, 2015, 193, .	0.2	0
344	MP51-18 ONE OUT OF TEN PATIENTS SUBMITTED TO RADICAL PROSTATECTOMY COMPLAINS OF POSTOPERATIVE PAINFUL ORGASM. Journal of Urology, 2015, 193, .	0.2	0
345	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
346	PD32-09 VERY LONG-TERM ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR NODE POSITIVE PROSTATE CANCER: A MULTI-INSTITUTIONAL, CONDITIONAL SURVIVAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
347	MP82-01 LONG-TERM OUTCOMES OF VERY HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT TREATMENTS. RESULTS OF A COMPETING RISKS, MULTI INSTITUTIONAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
348	MP56-18 NON-SURGICALLY RELATED CAUSES OF ERECTILE DYSFUNCTION AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY: RESULTS FROM A SINGLE INSTITUTION SERIES. Journal of Urology, 2015, 193, .	0.2	0
349	MP78-01 CONTEMPORARY MANAGEMENT OF PROSTATE CANCER PATIENTS SUITABLE FOR ACTIVE SURVEILLANCE: A POPULATION-BASED STUDY Journal of Urology, 2015, 193, .	0.2	0
350	Longâ€ŧerm outcomes of robotâ€assisted radical prostatectomy: Where do we stand?. BJU International, 2015, 116, 845-846.	1.3	0
351	Importance of prostate volume in the stratification of patients with intermediateâ€ r isk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	0.5	16
352	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. Prostate, 2015, 75, 1484-1491.	1.2	21
353	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	1.3	4
354	NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. Canadian Urological Association Journal, 2015, 9, 164.	0.3	7
355	Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?. Journal of Clinical Oncology, 2015, 33, 2831-2832.	0.8	2
356	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. Clinical Genitourinary Cancer, 2015, 13, 562-567.	0.9	37
357	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. Clinical Genitourinary Cancer, 2015, 13, e123-e130.	0.9	35
358	MP62-01 FUNCTIONAL OUTCOMES IN PATIENTS WITH CLINICALLY HIGH-RISK PROSTATE CANCER (PCA) TREATED WITH ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP). Journal of Urology, 2015, 193, .	0.2	0
359	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	1
360	Natural history of surgically treated high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 163.e7-163.e13.	0.8	101

#	Article	IF	CITATIONS
361	[11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 877-884.	3.3	38
362	Re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European–American Multi-institutional Analysis. Eur Urol 2015;68:86–94Re: Matthew Bultitude, Ben Challacombe. Simple Prostatectomy: A Step Too Far for Laparoscopy? Eur Urol 2015;68:95–6. European Urology, 2015, 68, e7-e8.	0.9	8
363	PD30-08 CANCER-CONTROL OUTCOMES IN PATIENTS WITH CLINICALLY HIGH-RISK PROSTATE CANCER (PCA) TREATED WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP): A MULTI-INSTITUTIONAL DATABASE ANALYSIS. Journal of Urology, 2015, 193, .	0.2	0
364	MP72-01 RADICAL CYSTECTOMY VERSUS BLADDER-SPARING TREATMENT FOR PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE URINARY BLADDER: A COMPARATIVE EFFECTIVENESS POPULATION-BASED STUDY Journal of Urology, 2015, 193, .	0.2	2
365	Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients. European Urology, 2015, 68, 497-505.	0.9	84
366	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 164.e1-164.e9.	0.8	35
367	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. European Urology, 2015, 68, 777-784.	0.9	48
368	A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2015, 68, 750-753.	0.9	34
369	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	1.2	36
370	Early radiotherapy after radical prostatectomy improves cancerâ€specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. International Journal of Urology, 2015, 22, 89-95.	0.5	22
371	Robot-assisted radical prostatectomy in prostate cancer. Future Oncology, 2015, 11, 2767-2773.	1.1	12
372	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. Current Oncology Reports, 2015, 17, 53.	1.8	7
373	Reply to C.G. Rusthoven et al. Journal of Clinical Oncology, 2015, 33, 1989-1989.	0.8	1
374	Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics. European Urology Focus, 2015, 1, 191-199.	1.6	5
375	Re: Paolo Gontero, Richard Sylvester, Francesca Pisano, et al. Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. Eur Urol 2015;67:74–82. European Urology. 2015. 67. e7.	0.9	3
376	Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. European Urology, 2015, 67, 157-164.	0.9	180
377	The Controversy That Will Not Go Away. European Urology, 2015, 67, 439-440.	0.9	3
378	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. European Urology, 2015, 67, 319-325.	0.9	14

#	Article	IF	CITATIONS
379	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. European Urology, 2015, 67, 299-309.	0.9	211
380	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	0.9	178
381	Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review. International Journal of Urology, 2015, 22, 22-32.	0.5	51
382	What Evidence Do We Need to Support the Use of Extended Pelvic Lymph Node Dissection in Prostate Cancer?. European Urology, 2015, 67, 597-598.	0.9	18
383	Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs. World Journal of Urology, 2015, 33, 873-880.	1.2	16
384	Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. European Urology, 2015, 68, 325-334.	0.9	239
385	Penile rehabilitation after radical prostatectomy: does it work?. Translational Andrology and Urology, 2015, 4, 110-23.	0.6	26
386	Assessing the impact on morbidity and mortality of neoadjuvant chemotherapy in patients with high-risk and muscle invasive bladder cancer eligible for radical cystectomy Journal of Clinical Oncology, 2015, 33, 331-331.	0.8	0
387	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. Canadian Urological Association Journal, 2014, 8, 695.	0.3	42
388	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. Canadian Urological Association Journal, 2014, 8, 419.	0.3	4
389	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Canadian Urological Association Journal, 2014, 8, 681.	0.3	51
390	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. Canadian Urological Association Journal, 2014, 8, 75.	0.3	11
391	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.3	78
392	Conditional survival after radical cystectomy. Nature Reviews Urology, 2014, 11, 8-9.	1.9	4
393	Survival after nephroureterectomy for upper tract urothelial carcinoma: A populationâ€based competingâ€risks analysis. International Journal of Urology, 2014, 21, 249-256.	0.5	20
394	The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats. Neurourology and Urodynamics, 2014, 33, 1251-1258.	0.8	16
395	Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3939-3947.	0.8	246
396	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	0.8	50

#	Article	IF	CITATIONS
397	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. JAMA Surgery, 2014, 149, 1039.	2.2	109
398	Reply to M. Valerio et al. Journal of Clinical Oncology, 2014, 32, 3681-3682.	0.8	0
399	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.3	46
400	Risk of Myocardial Infarction in Patients Receiving Testosterone Therapy. Annals of Pharmacotherapy, 2014, 48, 1665-1666.	0.9	0
401	Delay in Nephrectomy and Cancer Control Outcomes in Elderly Patients with Small Renal Masses. Urologia Internationalis, 2014, 92, 455-461.	0.6	15
402	MP37-20 INDIVIDUAL SURGEON COMMITMENT TO PELVIC LYMPH NODE DISSECTION RATHER THAN SURGICAL VOLUME IS A MAJOR DETERMINANT OF THE EXTENT OF NODAL DISSECTION DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
403	OP3-06 IMPACT OF TIME TO BIOCHEMICAL RECURRENCE ON CANCER-SPECIFIC MORTALITY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: A COMPETING-RISKS REGRESSION ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
404	PD15-07 ASSESSING THE OPTIMAL EXTENT OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH SINGLE PELVIC NODAL UPTAKE AT [11C]-CHOLINE PET/CT SCAN FROM RECURRING PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
405	MP51-15 TIME FROM SURGERY TO URINARY CONTINENCE SIGNIFICANTLY INFLUENCES THE SUBSEQUENT RECOVERY OF ERECTILE FUNCTION IN PATIENTS TREATED WITH BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	2
406	MP37-02 IMPACT OF SURGICAL VOLUME ON SURGICAL MARGIN STATUS IN PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
407	MP61-01 THE EXTENT OF PELVIC LYMPH NODE DISSECTION DOESÂNOTÂIMPACT ON CANCER SPECIFIC SURVIVA FORÂPATIENTSÂWITH LOCALLY ADVANCED BLADDER CANCER. Journal of Urology, 2014, 191, .	^{۱L} 0.2	0
408	Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. European Urology, 2014, 65, 554-562.	0.9	86
409	MP61-06 NEOADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH WORSE SHORT-TERM OUTCOMES IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY: A POPULATION-BASED STUDY. Journal of Urology, 2014, 191, .	0.2	0
410	Local tumor destruction in renal cell carcinoma—An inpatient population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 54.e1-54.e7.	0.8	10
411	MP60-04 IMPACT OF PRE-OPERATIVE HEMOGLOBIN VALUES AND PERI-OPERATIVE BLOOD TRANSFUSION ON CANCER SPECIFIC AND OVERALL MORTALITY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER: RESULTS FROM A SINGLE INSTITUTION COHORT. Journal of Urology, 2014, 191, .	0.2	0
412	MP37-07 COMPARATIVE EFFECTIVENESS OF ROBOTIC-ASSISTED VERSUS OPEN RADICAL PROSTATECTOMY CANCER CONTROL OUTCOMES. Journal of Urology, 2014, 191, .	0.2	0
413	MP2-16 MORBIDITY AND MORTALITY AFTER BENIGN PROSTATIC HYPERPLASIA SURGERY: DATA FROM THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM. Journal of Urology, 2014, 191, .	0.2	0
414	The impact of androgenâ€deprivation therapy (<scp>ADT</scp>) on the risk of cardiovascular (<scp>CV</scp>) events in patients with nonâ€metastatic prostate cancer: a populationâ€based study. BJU International, 2014, 114, E82-E89.	1.3	77

#	Article	IF	CITATIONS
415	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	0.9	29
416	A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease. European Urology, 2014, 65, 968-978.	0.9	364
417	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. European Urology, 2014, 65, 546-551.	0.9	81
418	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e21-29.e28.	0.8	28
419	Distribution of metastatic sites in patients with prostate cancer: A populationâ€based analysis. Prostate, 2014, 74, 210-216.	1.2	352
420	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. European Urology, 2014, 66, 561-568.	0.9	70
421	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competingâ€risks analysis. BJU International, 2014, 114, E62-E69.	1.3	20
422	High hospital volume reduces mortality after cystectomy. BJU International, 2014, 114, 5-6.	1.3	1
423	Re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node–Positive Prostate Cancer: A Systematic Review of the Literature. Eur Urol 2014;66:191–9. European Urology, 2014, 66, e107-e108.	0.9	2
424	Sentinel Node Biopsy for Prostate Cancer: A Useless Surgical Exercise?. European Urology, 2014, 66, 999-1000.	0.9	0
425	Mental health outcomes in elderly men with prostate cancer1Equal contribution Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
426	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	0.8	6
427	Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. Journal of Endourology, 2014, 28, 831-840.	1.1	64
428	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. Journal of Clinical Oncology, 2014, 32, 1419-1426.	0.8	169
429	Reply to Christopher Chee Kong Ho, Siew Eng Ho, Srijit Das' Letter to the Editor re: Giorgio Gandaglia, Alberto Briganti, Graham Jackson, et al. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease. Eur Urol 2014;65:968–78. European Urology, 2014, 66, e88-e89.	0.9	3
430	Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments. Journal of Endourology, 2014, 28, 784-791.	1.1	39
431	How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. Journal of Endourology, 2014, 28, 792-800.	1.1	22
432	Cisplatin-Based Chemotherapy and the Risk of Solid Tumors in Patients With Testicular Nonseminoma: Still a Matter of Debate. Journal of Clinical Oncology, 2014, 32, 1167-1167.	0.8	3

#	Article	IF	CITATIONS
433	Will Focal Therapy Remain Only an Attractive Illusion for the Primary Treatment of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 1299-1301.	0.8	31
434	The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination―period. European Journal of Surgical Oncology, 2014, 40, 1080-1086.	0.5	46
435	MP69-15 OUTCOME OF RADICAL PROSTATECTOMY FOR MISCLASSIFIED ACTIVE SURVEILLANCE CANDIDATES. Journal of Urology, 2014, 191, .	0.2	Ο
436	PD14-09 THE IMPACT OF ROBOTIC-ASSISTED RADICAL PROSTATECTOMY ON THE USE AND EXTENT OF PELVIC LYMPH NODE DISSECTION IN THE "POST-LEARNING CURVE―ERA. Journal of Urology, 2014, 191, .	0.2	0
437	PD12-04 THE EFFECT OF AGE AT DIAGNOSIS ON PROSTATE CANCER MORTALITY: A GRADE-FOR-GRADE AND STAGE-FOR-STAGE ANALYSIS. Journal of Urology, 2014, 191, .	0.2	0
438	MP50-09 COMPARATIVE EFFECTIVENESS OF RADICAL CYSTECTOMY VERSUS BLADDER-SPARING TREATMENT FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA: A POPULATION-BASED REPORT Journal of Urology, 2014, 191, .	0.2	0
439	PD12-12 ADJUVANT RADIOTHERAPY IMPROVES CANCER-SPECIFIC SURVIVAL ONLY IN PATIENTS WITH HIGHLY AGGRESSIVE PROSTATE CANCER. VALIDATION OF RECENTLY RELEASED CRITERIA. Journal of Urology, 2014, 191, .	0.2	1
440	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	0.9	97
441	MP69-01 CAN WE CONSIDER PATIENTS WITH LIMITED BIOPSY GLEASON SCORE 3+4 ELIGIBLE FOR ACTIVE SURVEILLANCE?. Journal of Urology, 2014, 191, .	0.2	Ο
442	MP51-19 COMPARATIVE EFFECTIVENESS OF ROBOTIC-ASSISTED AND OPEN RADICAL PROSTATECTOMY IN THE "POST-LEARNING CURVE―ERA. Journal of Urology, 2014, 191, .	0.2	0
443	OP3-05 LONG-TERM ONCOLOGIC OUTCOMES OF LAPAROSCOPIC RENAL CRYOABLATION: 10 YEARS RESULTS FROM A SINGLE INSTITUTION. Journal of Urology, 2014, 191, .	0.2	0
444	Reply to E. David Crawford and Bo-Eric Persson's Letter to the Editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026. European Urology, 2014, 66, e36-e37.	0.9	1
445	MP60-11 90-DAY MORTALITY REPRESENTS A MORE REALISTIC ENDPOINT THAN 30-DAY MORTALITY AFTER RADICAL CYSTECTOMY. Journal of Urology, 2014, 191, .	0.2	Ο
446	MP10-19 DEVELOPMENT AND EXTERNAL VALIDATION OF A PROGNOSTIC TOOL FOR PREDICTION OF CANCER-SPECIFIC MORTALITY AFTER COMPLETE LOCO-REGIONAL PATHOLOGICAL STAGING FOR SQUAMOUS CELL CARCINOMA OF THE PENIS. Journal of Urology, 2014, 191, .	0.2	0
447	MP78-07 THE IMPORTANCE OF OTHER CAUSE MORTALITY AND CARDIOVASCULAR MORBIDITY IN PATIENTS WITH METASTATIC PROSTATE CANCER EXPOSED TO CONVENTIONAL ANDROGEN DEPRIVATION THERAPY. Journal of Urology, 2014, 191, .	0.2	Ο
448	Editorial Comment. Urology, 2014, 83, 630-631.	0.5	0
449	PD12-11 SURVIVAL BENEFIT OF RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY ADVANCED PROSTATE CANCER: ESTIMATIONS OF THE NUMBER NEEDED TO TREAT BASED ON COMPETING-RISKS ANALYSIS. Journal of Urology, 2014, 191, .	0.2	2
450	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25

#	Article	IF	CITATIONS
451	The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis. European Journal of Surgical Oncology, 2014, 40, 1706-1715.	0.5	15
452	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2014, 66, 479-486.	0.9	121
453	Will Active Surveillance for Clinically Localized Prostate Cancer Survive in the Era of Individualized Medicine?. European Urology, 2014, 66, 186-187.	0.9	2
454	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report Journal of Clinical Oncology, 2014, 32, 334-334.	0.8	1
455	Using adjuvant radiotherapy to improve cancer-specific survival in patients with highly aggressive prostate cancer: Examining recently released criteria Journal of Clinical Oncology, 2014, 32, 30-30.	0.8	1
456	Population-based comparison of surgical margin status for robotic versus open radical prostatectomy Journal of Clinical Oncology, 2014, 32, 51-51.	0.8	1
457	Readmissions after major urologic cancer surgery. Canadian Journal of Urology, 2014, 21, 7537-46.	0.0	24
458	Nerveâ€sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. BJU International, 2013, 111, 717-722.	1.3	108
459	Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. Endocrine, 2013, 43, 285-292.	1.1	32
460	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-967.	0.4	16
461	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerveâ€sparing radical prostatectomy. International Journal of Urology, 2013, 20, 413-419.	0.5	21
462	2235 THE NUMBER OF BIOPSY CORES TAKEN IS A MAJOR PREDICTOR OF UNFAVORABLE PROSTATE CANCER AT FINAL PATHOLOGY IN PATIENTS CANDIDATE FOR ACTIVE SURVEILLANCE: CLINICAL IMPLICATIONS. Journal of Urology, 2013, 189, .	0.2	0
463	Incidence of Priapism in Emergency Departments in the United States. Journal of Urology, 2013, 190, 1275-1280.	0.2	75
464	962 PREDICTION OF LONG-TERM CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LYMPH NODE INVASION: RESULTS OF CONDITIONAL SURVIVAL ANALYSES. Journal of Urology, 2013, 189, .	0.2	0
465	113 TADALAFIL IMPROVES HYPOXIA, STRUCTURAL DETRUSOR CHANGES AND BLADDER COMPLIANCE AFTER CAVERNOUS NERVE INJURY. Journal of Urology, 2013, 189, .	0.2	1
466	Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States. Journal of Urology, 2013, 190, 1798-1804.	0.2	15
467	247 SPATIAL DISTRIBUTION OF POSITIVE CORES DECREASES MISCLASSIFICATION RATES OF PATIENTS WITH LOW RISK PROSTATE CANCER CANDIDATE FOR ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.2	0
468	1618 IMPACT OF URINARY DIVERSION ON CANCER SPECIFIC-SURVIVAL IN PATIENTS WITH BLADDER CANCER AND PATHOLOGIC POSITIVE LYMPH NODES. Journal of Urology, 2013, 189, .	0.2	0

#	Article	IF	CITATIONS
469	114 INHIBITION OF PERIPHERAL FATTY ACID AMIDE HYDROLASE AMELIORATES BLADDER OVERACTIVITY IN SPONTANEOUSLY HYPERTENSIVE RATS. Journal of Urology, 2013, 189, .	0.2	0
470	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. Cancer Epidemiology, 2013, 37, 219-225.	0.8	222
471	The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (<scp>BPH</scp>). BJU International, 2013, 112, 432-441.	1.3	211
472	Perioperative Betamethasone Treatment Reduces Signs of Bladder Dysfunction in a Rat Model for Neurapraxia in Female Urogenital Surgery. European Urology, 2012, 62, 1076-1085.	0.9	19
473	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.2	35
474	25 THE FATTY ACID AMIDE HYDROLASE INHIBITOR OLEOYL ETHYL AMIDE INCREASES BLADDER STORAGE CAPACITY AND REDUCES DETRUSOR OVERACTIVITY IN RATS. Journal of Urology, 2012, 187, .	0.2	1
475	31 THE LONG-ACTING GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONIST DEGARELIX HAS PROTECTIVE EFFECTS ON BLADDER FUNCTION AFTER OUTFLOW OBSTRUCTION IN RATS. Journal of Urology, 2012, 187, .	0.2	0
476	114 THE PERIPHERAL-ACTIVE FAAH INHIBITOR URB-937 COUNTERACTS DETRUSOR OVERACTIVITY IN FEMALE RATS. Journal of Urology, 2012, 187, .	0.2	0
477	768 DO NODAL METASTASES INVARIABLY IMPACT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER? IMPORTANCE OF LOCAL DISEASE STATUS. Journal of Urology, 2012, 187, .	0.2	0
478	770 A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	0
479	772 PREDICTORS OF LONG-TERM SURVIVAL OF PATIENTS WITH HIGH VOLUME OF NODAL METASTASES AT EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER. THE IMPORTANCE OF AN INTEGRATED, MULTIMODAL APPROACH. Journal of Urology, 2012, 187, .	0.2	0
480	1125 A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
481	1379 THE KEY ROLE OF TIME IN PREDICTING POST-RADICAL PROSTATECTOMY ERECTILE FUNCTION RECOVERY: CONDITIONAL SURVIVAL ANALYSES. Journal of Urology, 2012, 187, .	0.2	0
482	1576 INHIBITION OF SPINAL FATTY ACID AMIDE HYDROLASE MODIFIES MICTURITION DURING CYSTOMETRY IN AWAKE RATS. Journal of Urology, 2012, 187, .	0.2	0
483	Expression of Fatty Acid Amide Hydrolase (FAAH) in Human, Mouse, and Rat Urinary Bladder and Effects of FAAH Inhibition on Bladder Function in Awake Rats. European Urology, 2012, 61, 98-106.	0.9	45
484	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve‧paring Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.3	17
485	2271 RADICAL PROSTATECTOMY AFTER PREVIOUS PROSTATE SURGERY: CLINICAL AND FUNCTIONAL OUTCOMES. Journal of Urology, 2011, 185, .	0.2	0
486	800 DEGARELIX REDUCES URODYNAMIC CHANGES IN A RAT MODEL FOR EXPERIMENTAL DETRUSOR OVERACTIVITY AND PRODUCES MORE EFFICIENT VOIDING. Journal of Urology, 2011, 185, .	0.2	2

#	Article	IF	CITATIONS
487	365 ROLE OF THE SELECTIVE UPPER URINARY TRACT CYTOLOGY IN PATIENTS WITH SUSPICIOUS TRANSITIONAL LESIONS. Journal of Urology, 2011, 185, .	0.2	0
488	1408 A NEW MULTIMODAL ANESTHESIOLOGICAL AND NUTRITIONAL APPROACH IN RADICAL CYSTECTOMY WITH URINARY DIVERSION BASED ON ILEAL SEGMENT: A SINGLE-CENTRE, PROSPECTIVE, RANDOMIZED STUDY. Journal of Urology, 2011, 185, .	0.2	1

29